INTRODUCTION
Colon cancer (CC) is a common and fatal disease. It is estimated that about 95520 CC cases are diagnosed annually in the United States. CC is the third most common cancer in men and the second most common cancer in women. Despite a declining mortality since 1990, it ranked the third in women and the second in men in cancer-related deaths. From 1992 to 2012, the incidence of men and women under the age of 50 diagnosed with CC increased by 2.1% per year. These increases were primarily seen in left-sided cancers, and particularly in rectal cancer (3.9% per year). Approximately 39% of the cases are local, and 37% are locoregional at diagnosis. Seventy to 80% of patients with locoregional disease at diagnosis are suitable for curative surgery. While surgery is essential for curative treatment, some patients have recurrence even after curative surgery. The prognosis is worse after recurrence. For this reason, it is important to identify reliable factors for identification of patients at high risk of recurrence [1, 2] . The proximal and distal segments of the colon possess different embryological origins. The segment extending from the caecum to the proximal two-thirds of the transverse colon develops from the midgut. The part from the distal third of the transverse colon to the rectum develops from the hindgut. While the right colon consists of the caecum, ascending colon, hepatic flexure, and transverse colon, the left colon consists of the splenic flexure, descending colon, and sigmoid colon. Blood supply, innervation, and lymphatic drainage anatomically differ between the right and left colon. Considering these differences in anatomy and embryological origin, variation in clinical features may be identified for the same disease of the colon [2] . It has been known for many years that right CC (RCC) and left CC (LCC) represent dissimilar tumors with differences in epidemiology, biology, pathology, and clinical outcomes. Recently, the relationship between tumor localization and prognosis in metastatic disease has been investigated. These studies, however, primarily focused on responses to chemo-or targeted therapy [3, 4] . For this reason, it is still not clear for patients and clinicians whether tumor localization is an important additional risk factor in locoregional disease.
In our study, we aimed to examine the association of tumor localization to disease free survival (DFS) and overall survival (OS) in patients who underwent curative surgery for stage Ⅱ and Ⅲ CC.
MATERIALS AND METHODS

Patients
This retrospective study included patients who were followed up in the oncology outpatient clinic of Okmeydani Training and Research Hospital between 1995 and 2017. Clinical and pathological data were obtained from medical patient records. Those with rectal cancer, another malignancy distinct from CC, multiple primary tumors, metastatic disease, patients under 18 years and those without sufficient data were not included in the study. A total of 942 patients with full medical records and a pathological diagnosis of stage Ⅱ-Ⅲ CC were identified. The study was approved by the institutional ethics committee. 
Data collection
RESULTS
The rates of RCC and LCC were 48.4% (n = 456) and 51.6% (n = 486), respectively. Male patients constituted 54.2%. The median patient age was 58 years (range: 19-94 years). Nearly one-third of patients (32.5%) were equal to or above 65 years old (Table 1) . Twenty-six patients (2.8%) had a family history of CC in their first-degree relatives. The history of smoking and regular alcohol use was present in 45.8% (n = 350) and 5.2% (n = 49) of patients, respectively. Emergency surgery was performed in 151 patients (16%). DM and HT were present in 9.9% and 23.7% of the study population, respectively ( Table 1) .
Analysis of tumor histology showed mucinous adenocarcinoma in 17.3% of patients, grade Ⅲ tumor in 6.7% of patients, and stage Ⅱ disease in the majority of patients (60.2%). The rates of pT3 and pT4 were 79.8% and 6.1%, respectively. The mean number of lymph node dissections performed was 17.57 ± 10.8, where lymph node involvement was 1.48 ± 4.0. The rate of lymph node dissection below 12 was 31.4%. The number of patients with pN2 and pN1 were 102 (10.8%) and 273 (29%), respectively. PNI and LVI positivity was found in 21.7 and 32.2% of patients, respectively. Eight patients (0.8%) had positive surgical margins (Table 1) .
Postoperative systemic therapy was initiated in 734 patients (77.9%), 67.2% (n = 493) of which received 5-FU-based (5-fluorouracil + leucovorin, capecitabine) and 32.8% (n = 241) received oxaliplatin-based (capecitabine + oxaliplatin, 5-fluorouracil + leucovorin + oxaliplatin) regimens. A total of 695 patients (94.7%) completed planned adjuvant chemotherapy regimens (Table 1) .
During the median follow-up of 90 mo (range: 6-252 mo), 138 (14.6%) patients developed recurrence, and 40 (29.0%) of recurrences were locoregional and 98 (71.0%) were distant and 95 (9.1%) of patients died. Metastasectomy was performed for 48 of patients with recurrence (Table 1) .
No statistical difference existed between RCC and LCC in terms of gender, smoking and alcohol use, history of DM and HT, tumor grade, stage, pT stage, pN stage, LVI and PNI positivity, positive surgical margins, adjuvant therapy use, the regimen used for adjuvant therapy, rates for recurrence (locoregional or distant), metastasectomy and death. Rate of mucinous adenocarcinoma histology, rate of LN number of ≥ 12, and the mean number of LNs dissected were significantly higher in the RCC group (P = 0.002, P < 0.001, and P < 0.001, respectively) ( Table 2 ).
In patients with stage Ⅱ and Ⅲ disease with or without adjuvant therapy, DFS was similar in terms of primary tumor localization (stage Ⅱ; log rank P = 0.547 and log rank P = 0.481, respectively; stage Ⅲ; log rank P = 0.976 and log rank P = 0.978, respectively). In stage Ⅲ disease, there was no statistically significant difference for DFS in patients receiving 5-FU-based or oxaliplatin-based regimens according to tumor location (log rank P = 0.518 and log rank P = 0.638, respectively) ( Figure 1 ).
In patients with stage Ⅱ and Ⅲ disease with or without adjuvant therapy, OS was not statistically significant with respect to primary tumor localization (stage Ⅱ; log rank P = 0.381 and log rank P = 0.947, respectively; stage Ⅲ; log rank P = 0.378 and log rank P = 0.904, respectively). In stage Ⅲ disease, there was no statistically significant difference for OS in patients receiving 5-FU-based or oxaliplatin-based regimens according to tumor location (log rank P = 0.113 and log rank P = 0.806, respectively) ( Figure 2 ). No statistically significant difference was detected between median survival after recurrent/metastatic (OS2) RCC (26 ± 6.2 mo) and LCC (34 ± 4.9 mo) cases (log rank P = 0.092) (Figure 3) .
Univariate analysis for DFS showed statistically significant factors as age ≥ 65 years, presentation with ileus, stage, pT stage, pN stage, dissected LN < 12, PNI, LVI, surgical margin positivity, and adjuvant therapy (P = 0.001, P = 0.003, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P = 0.008, and P = 0.041, respectively). In multivariate analysis, age ≥ 65 years, presentation with ileus, stage, dissected LN < 12, PNI, LVI, and adjuvant therapy were detected as statistically significant factors (P = 0.001, P = 0.011, P < 0.001, P = 0.012, P < 0.001, P = 0.003, and P = 0.005, respectively) ( Table 3) .
Univariate analysis for OS revealed statistically significant factors as age ≥ 65 years, HT, stage, pT stage, pN stage, PNI, LVI, and adjuvant therapy (P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, and P = 0.017, respectively). In multivariate analysis, age ≥ 65 years, stage, PNI, LVI, and adjuvant therapy were found to be statistically significant factors (P < 0.001, P = 0.036, P = 0.001, P < 0.001, and P = 0.011, respectively) ( Table 4) .
DISCUSSION
In this trial, we aimed to investigate whether tumor location had prognostic significance in patients who underwent curative surgery for stage Ⅱ or Ⅲ CC with or without adjuvant therapy. In our study, we found that primary tumor localization had no effect on DFS and OS. A number of studies have been conducted in different regions of the world to describe the differences between RCC and LCC [5] [6] [7] [8] [9] [10] . The data related to the prognosis of RCC and LCC are contradictory in recent studies [5] [6] [7] [8] [9] 11] . Most studies reported patients with RCC as likely to be older, often female, in advanced stages, and poorly differentiated [6] [7] [8] [9] [10] [11] [12] . In their study of 1224 patients, Mik et al [5] reported that RCC patients were older than LCC patients, with a median age of 67.8 years. LCC patients were likely to have operations for emergent indications. The number of dissected lymph nodes were reported to be higher in RCC (11.7 ± 6 vs 8.3 ± 5, P = 0.0001) [5] . In another study, the likelihood of RCC was associated with increased age. In addition, T4 tumor, poor differentiation rate, and presence of venous invasion were detected to be significantly higher in RCC [6] . In our study, the median age was 58 years (range: 19-94 years). Similarly, in our study, LCC patients were more likely to have operations for emergent indications. Likewise, mucinous type was significantly more common in RCC. Unlike other studies, we did not detect significant differences between RCC and LCC in terms of age, gender, pT stage, stage, LVI, and PNI [5] [6] [7] [8] [9] [11] [12] [13] . Lim et al [7] followed 414 patients with stage Ⅰ-Ⅲ WJGO|www.wjgnet.com 82.1% for RCC and 86.7%, 84.2%, and 83.4% for LCC, respectively. In patients with stage Ⅱ and Ⅲ disease with or without adjuvant therapy, DFS was similar in terms of primary tumor localization. Independent risk factors for recurrence included age ≥ 65 years, presentation with ileus, advanced stage, dissected number of LNs < 12, and presence of PNI and LVI. In the study by Aoyama et al [9] , three and fiveyear median OS rates were 87.6% and 81.6% for RCC and 91.5% and 84.5% for LCC, where the difference was statistically significant (P < 0.009). Investigators have emphasized that this difference might originate from the fact that RCC patients were more likely to be older and to have poorly differentiated and mucinous histology [9] . A Far East study performed with 4426 RCC,
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CC with a median duration of 66.7 mo, during which the 5-year DFS was significantly higher in LCC (88.3%) than in RCC (81.4%). In multivariate analysis, pT3-4, pN1-2, and histologic grades were reported to be prognostic factors for DFS [7] . Moritani et al [8] recruited 820 stage Ⅰ to Ⅲ patients with a median follow-up of 55.8 ± 34.9 mo. No statistically significant difference was reported between RCC and LCC in five-year DFS (RCC 88.6%, LCC 89.4%, P = 0.231) [8] . Another study had 4029 stage Ⅰ to Ⅲ patients, for which the median follow-up was five years. While three-and five-year DFS rates of patients with RCC were 79.8% and 76.7%, it was 82.0% and 77.6% for LCC, respectively, with no statistically significant difference (P = 0.35) [9] . Five, ten, and 15-year DFS were 87.5%, 84.0%, and
WJGO|www.wjgnet.com Ⅰ to Ⅲ. Analysis by stage indicated lower mortality at stage Ⅱ of LCC than RCC and higher mortality at stage Ⅲ of LCC than RCC [12] . Warschkow et al [13] reported 5-year OS rate for patients with RCC as 65.1% (95%CI: 64.6-65.6) and LCC as 72.1% (95%CI: 71.5-72.6). The prognosis of RCC in stages Ⅰ and Ⅱ was reported as better overall. RCC and LCC had a similar prognosis at stage Ⅲ. In multivariate analysis, there was no difference between RCC and LCC in terms of 5-year OS [13] . In another study by Huang et al [14] , with 1095 patients at all stages and at all sites including the rectum, only in stage 3 disease were right colon localized tumors worse for survival.
In our study, OS rates at five, ten, and 15 years were found as 91.2%, 87.1%, and 85.2% in RCC compared 418 LCC and rectal cancer patients in all stages reported significantly longer DFS and OS in LCC than those in RCC in univariate analysis, yet survival failed to show significant difference by localization in multivariate analysis. The authors concluded that primary tumor localization was not an independent prognostic factor in Chinese patients with stage Ⅰ-Ⅲ colorectal cancer (CRC) [10] . Patel et al [6] recruited stage Ⅱ-Ⅲ CRC patients, 40% of which were RCC and 31% of which had rectal cancer. Merely 45% of stage Ⅲ CRC cases had received adjuvant therapy. No correlation was found between survival and tumor localization in patients receiving and not receiving adjuvant treatment [6] . Weis et al [12] reported no difference in 5-year mortality between RCC and LCC of any stage with stage
WJGO|www.wjgnet.com may have affected the analyses. In our study, patients from all age groups (19-94 years) were included, and the median age was lower than that in other studies. In addition, the duration of median follow-up in our study was 90 mo (6-252 mo), which was longer than that in all other studies [14] [15] [16] . Besides, our study only included stage Ⅱ and Ⅲ patients, unlike other studies [4, 5, 8, [15] [16] [17] [18] . In our study, family history and comorbidities were added to the analysis, where those receiving and not receiving adjuvant therapies were assessed separately.
The causes of the inconsistent relationship between mortality and tumor localization are most likely related to tumor biology. Microsatellite instability (MSI) and BRAF mutations are more likely to be found in RCC than in LCC. BRAF mutations have been reported to be associated with poor prognosis [13, 18] . On the other hand, MSI was reported to have a positive effect on the prognosis of stage Ⅱ CRC [13] . Perhaps the most important limitation of our study is the absence of BRAF and MSI data of patients. It is not known how the MSI and BRAF situation affects the results of the study. In our study, the number of dissected LNs was lower than that in RCC, and the percentage of patients with < 12 dissected LN number were higher in LCC. This might have affected DFS and OS in LCC. In addition, our study did not analyze disease-specific survival; therefore, some of the mortal events might have occurred for non-cancer reasons during the long follow-up period.
In conclusion, tumor localization was not found to be associated with DFS or OS in stage Ⅱ and Ⅲ CC patients who were treated with or without adjuvant therapy. However, it was observed that OS was worse in RCC patients after recurrence. Further large and prospective studies also involving MSI and BRAF status are warranted.
ARTICLE HIGHLIGHTS
Research background
It is well known that metastatic right colon cancer (RCC) is more aggressive than left colon cancer (LCC). However, the effects of tumor location on the decision of adjuvant therapy and survival are not clearly known in early stage disease.
Research motivation
In recent trials, prognosis data of early stage RCC and LCC are conflicting. The uncertainty of whether tumor localization is functioning as an important additional risk factor for patients and clinicians in locoregional disease is still present.
Research objectives
In our study, we examined the effect of tumor localization on survival in patients who received or did not receive adjuvant therapy for stage Ⅱ and Ⅲ colon cancer. We also investigated the effects of chemotherapy regimens in stage Ⅲ disease on survival in terms of tumor site.
Research methods
In the study, a total of 942 patients with stage Ⅱ-Ⅲ colon cancer, excluding rectal cancer, were included. Comorbidities (diabetes mellitus, hypertension), 419 to 93.8%, 88.1%, 88.1% in LCC. There was no significant difference between stage 2 and stage 3 RCC and LCC patients without adjuvant treatment. Despite having a slightly higher mortality in RCC, especially in stage Ⅲ patients receiving 5-FU-based regimens, but this difference did not reach statistical significance in terms of primary tumor localization in stage Ⅱ and Ⅲ patients. Age ≥ 65 years, advanced stage, PNI, and LVI were found to be the most statistically significant factors for mortality in multivariate analysis.
The relationship between tumor localization and prognosis in metastatic disease has been investigated, and studies reported worse prognosis of the right colon than the left colon [3, 4, 15] . In a study of 1947 patients with metastatic disease, the median OS was 14 mo (95%CI: 12.7-15.3 mo) in RCC and 20.5 mo (95%CI: 18.5-22.5) in LCC, and this difference was statistically significant (P < 0.001) [15] . In another study by Lee et al [16] using Australian CRC registry data, the post-recurrence survival in early stage patients was worse in right CC. In a study by Kerr et al [17] , after recurrence, the median OS was 1.25 years and 2.25 years in RCC and LCC, respectively. In the subgroup analysis of 138 patients with recurrence in our study, median OS was 26 mo (95%CI: 13.7-38.2) in RCC and 34 mo (95%CI: 24.3-43.6) in LCC, where the difference did not reach statistical significance, possibly due to the small number of cases (P = 0.092).
It is known that in recent years, the incidence of CC at younger ages has increased [1] . Surveillance, Epidemiology, and End Results (SEER) trials usually involve elderly patients, and data on comorbidities and family history are not available in the SEER database [11, 12] . It is not clear how much these parameters WJGO|www.wjgnet.com 
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Sakin A et al . Primary tumor localization in stage II and III colon cancer family histories, adjuvant therapy status and chemotherapy regimens were added to the analysis. The tumors from the caecum to the splenic flexure were defined as RCC and those from the splenic flexure to the sigmoid colon as LCC.
Research results
There was no difference for age and gender in the groups. Mucinous adenocarcinoma rate and the number of removed lymph nodes was higher in the RCC group. Recurrence and mortality risk was lower in patients with adjuvant treatment for all stages. In patients with stage Ⅱ and Ⅲ disease with or without adjuvant therapy, disease free survival and overall survival were similar in terms of primary tumor localization. In stage Ⅲ disease, there was no statistically significant difference for disease free survival and overall survival in patients receiving 5-Fluorouracil (commonly known as 5-FU)-based or oxaliplatinbased regimens according to tumor location. After recurrence, RCC was more aggressive.
Research conclusions
In conclusion, our study showed no association of tumor localization with either disease free survival or overall survival in patients with stage Ⅱ or Ⅲ colon cancer managed with or without adjuvant therapy. However, after recurrence, RCC was more aggressive.
Research perspectives
Further large and prospective studies also involving microsatellite instability and BRAF status are needed to determine the effectiveness of tumor location on decision of adjuvant therapy in patients with stage Ⅱ-Ⅲ colon cancer.
